Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Lactobacillus rhamnosus HN001 and Reduced SCORAD Score

Doses used in studies

CFU/day: 6 billion (median 6 billion, IQR 6 billion–6 billion) — 2 studies

Safety in these studies

Overall tolerabilityReported
This study showed that the protective effect of HN001 against eczema... extended to at least 4 years of age.
from: A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years o

2 of 2 papersPopulation:

Maternal supplementation alone with Lactobacillus rhamnosus HN001 during pregnancy and breastfeeding does not reduce infant eczema
- 2018-04-06
- RCT
- Pediatric Allergy and Immunology 29(3)
- - K. Wickens
  - C. Barthow
  - E. Mitchell
  - T. Stanley
  - G. Purdie
  - Judy Rowden
  - Janice Kang
  - Fiona Hood
  - L. V. D. van den Elsen
  - Elizabeth E Forbes-Blom
  - I. Franklin
  - Phillipa Barnes
  - P. Fitzharris
  - Robyn M. Maude
  - P. Stone
  - P. Abels
  - R. Murphy
  - J. Crane
- PubMed: 29415330
- DOI: 10.1111/pai.12874
7 Insights on
- Reduced SCORAD Score
- High evidence
- Rigorous Journal
- Mixed
Maternal-only HN001 supplementation did not significantly reduce ... SCORAD ≥ 10
Effect
Neutral
Effect size
Small
Significant
No
Dose
6 × 10^9 colony-forming units daily
A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years
- 2012-06-15
- RCT
- Clinical & Experimental Allergy 42(7)
- - K. Wickens
  - Peter N. Black
  - Thorsten Stanley
  - Edwin A. Mitchell
  - C. Barthow
  - P. Fitzharris
  - Gordon Purdie
  - Julian Crane
- PubMed: 22702506
- DOI: 10.1111/j.1365-2222.2012.03975.x
6 Insights on
- Reduced SCORAD Score
- High evidence
- Highly Cited
nonsignificant reductions in the cumulative prevalence of SCORAD ≥ 10 (HR 0.74 (95% CI 0.52-1.05))
Effect
Neutral
Effect size
Small
Significant
No
Dose
6 × 10^9 cfu/day